MedTrace Logo

Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)

NCT03131726 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-09-25

No results posted yet for this study

Summary

In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy treated with simvastatin or no treatment.

Conditions

  • Graves Ophthalmopathy
  • Thyroid Associated Ophthalmopathy
  • Thyroid Associated Orbitopathy

Interventions

DRUG

Simvastatin 40mg

see arm description

Sponsors & Collaborators

  • Region Skane

    collaborator OTHER

  • Lund University

    lead OTHER

Principal Investigators

  • Tereza Planck, MD, PhD · Lund University and Skåne University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-26
Primary Completion
2027-01-26
Completion
2028-03-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03131726 on ClinicalTrials.gov